GSKCONS Charts, Analysis and Tips

home > trading-and-exports > gskcons

Technical Analysis

Technical Strength: 6.7 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 59.6. According to RSI analysis, gskcons is technically strong. 9.0 GSKCONS RSI Chart
MACD (?) MACD: 78.6 and Signal Line: 95.6. According to MACD analysis, gskcons is marginally weak. 3.0 GSKCONS MACD Chart
Simple Moving Average (?) According to simple moving average analysis, gskcons is in a strong uptrend. Major support levels are 6471.922, 6233.161, 5502.49. 10.0 GSKCONS Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, gskcons is in a strong uptrend. Major support levels are 6417.882, 6176.82, 5670.554. 10.0 GSKCONS Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.611. 5.0 GSKCONS Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 5993.064 and 5775.0. Resistance level is 6699.0. 6.5 GSKCONS Fibonacci Retracement Chart
Average True Range (?) ATR: 143 NA GSKCONS Average True Range Chart
Average Directional Index (?) ADX is 45.2 which means GSKCONS is in a trend. NA GSKCONS Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
January 16, 2018
Open Price 6463.55
High Price 6587.0
Low Price 6460.0
Close Price 6507.05
Absolute Change 0.6
Percentage Change 0.00922%
Weekly Change 3.28%
Monthly Change 2.11%
Yearly Change 26.5%
52-week high 6699.0
52-week low 4851.0
Corporate Actions
ExDate Purpose
August 02, 2017 AGM/DIV-RS 70/- PER SHARE
July 26, 2016 AGM/DIV-RS 70 PER SHARE
July 27, 2015 AGM/DIV-RS 55 PER SHARE
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.347
Confidence in Beta1.78%
Market Capital Rs. 27365.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 163.32
TTM Price-to-Earnings (P/E) Ratio 39.8
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 16 January 2018: Deliverable Quantity:3.74e+03 NA GSKCONS Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 16 January 2018: Daily Volatility:0.2388 NA GSKCONS Annualized Daily Volatility (Spot Price) Chart


December 14, 2017 GlaTrading WindowaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
December 08, 2017 GSKReply to Clarification SoughtKCONS:The Exchange had sought clarification from GlaxoSmithKline Consumer Healthcare Limited with respect to announcement dated 06-Dec-2017, regarding Change in Director(s) of the company.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is as follow- Mr Navneet Saluja has completed his MBA from Jamnalal Bajaj Institute of Management in 1987. Mr Navneet Saluja started his career with Cadbury India as a Management Trainee. He then had a long and successful stint with Gillette India. In his last role with Gillette, Mr Navneet Saluja was the VP Sales when he successfully restructured the sales & distribution network for the company. He has also worked with Kelloggs India, as the Sales & Marketing Director, where he drove improvement in gross margins and operating profits. Mr Navneet Saluja has worked as the CEO for Reliance Retail for Delhi and Haryana Region. He also worked as the CEO for Reliance Infocom. In both the roles, he was responsible for general management of business. Mr Navneet Saluja joined GSK India in 2008, initially as the Sales Head for India. Subsequently he was appointed as the Area GM Middle East. Following consolidation with Africa earlier this year, he has successfully led the MEA area to consistently deliver strong commercial performance.
See all Announcements

Board Meetings

Date Meeting Date Purpose
October 27, 2017 November 07, 2017 ToResultso, inter alia, consider and take on record the Unaudited Financial Results for the quarter ended September 30, 2017 with Limited Review by Statutory Auditors.
July 11, 2017 August 08, 2017 To,Results, inter-alia, consider and take on record the unaudited Financial Results for the quarter ended June 30, 2017 with Limited Review by Auditors.
See all Board Meetings

GSKCONS is part of...

Index Weightage

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 6322 Rs. 6391 Rs. 6449 Rs. 6518 Rs. 6576 Rs. 6645 Rs. 6703